Narcolepsy type 1 affects far more than daytime sleepiness. For many patients, managing the condition means dealing with a range of symptoms linked to the loss of orexin signaling. Orzeyful (oveporexton) brings a new approach by directly targeting this underlying pathway.
As an oral orexin receptor 2 agonist, Orzeyful is designed to restore the signaling that is disrupted in narcolepsy type 1. Its arrival marks a shift from managing individual symptoms to addressing the biology behind the condition.
For clinical trial and first-to-file teams, Orzeyful is a molecule worth tracking as its market adoption and availability develop in the CNS space.
